false 0001781174 0001781174 2024-09-14 2024-09-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2024
Acrivon Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-41551 |
|
82-5125532 |
| (State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
| 480 Arsenal Way, Suite 100 Watertown, Massachusetts |
|
02472 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(617) 207-8979
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
|
ACRV |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure |
On September 14, 2024, Acrivon Therapeutics, Inc. (the “Company”) issued a press release reporting Phase 2 clinical data of ACR-368 in patients with endometrial cancer that the Company presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain on September 14, 2024. The press release also announced that the Investigational New Drug application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024. The press release also provided progress updates on the Company’s AP3 Interactome, the Company’s proprietary, computational analytics platform.
On September 14, 2024, the Company hosted a virtual corporate R&D event, where the Company reviewed the ACR-368 clinical data, ACR-2316 updates, and the progress on the Company’s AP3 Interactome platform. The Company also reiterated previous guidance that the Company expects that its existing cash, cash equivalents and investments of $220.4 million as of June 30, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2026. Copies of the press release and the presentation from the corporate R&D event are attached hereto as Exhibits 99.1 and 99.2 and incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
The information set forth under Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ACR-368 Phase 2 Clinical Data
On September 14, 2024, the Company presented clinical data at ESMO Congress 2024 from its ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The data were based on 35 safety-evaluable subjects, of which 23 (8 OncoSignature-positive and 15 OncoSignature-negative) were efficacy-evaluable with at least one on-treatment scan. The data presented was based on data available from the trial’s electronic data capture system as of July 25, 2024.
A confirmed objective response rate (“ORR”) (RECIST 1.1) of 62.5% (95% CI, 30.4-86.5) was observed in the cohort of prospectively-selected OncoSignature-positive patients who were efficacy-evaluable and who had all progressed on prior anti-PD-1 therapy. All confirmed responders continued to be on treatment and median duration of response had not yet been reached (~6 months at time of data cut-off).
Best overall response in last prior line predominantly progressive disease in confirmed ACR-368 responders.
The data further validated the Company’s AP3-based ACR-368 OncoSignature assay, which is used for prospective patient selection in this registrational intent trial, achieving a clear segregation of responders in the OncoSignature-positive versus OncoSignature-negative arms (p-value = 0.009).
Further evidence of sensitization to ACR-368 by ultra-low dose gemcitabine in a proportion of OncoSignature-negative subjects was observed, with an initial disease control in 8 out of 15 subjects, including 1 confirmed complete response.
Consistent with past trials and earlier reported data, the ACR-368 treatment-related adverse events were limited, predominantly transient, reversible, mechanism-based hematological adverse events, which typically occurred during the first 1-2 cycles of therapy. There was a notable absence of long-lasting myelosuppression, or the typical more severe non-hematological adverse events commonly seen with antibody-drug conjugates and chemotherapy.
ACR-2316 Updates
The Company also announced that the Investigational New Drug application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated ahead of schedule, and first-in-human dosing for the Phase 1 study now expected in the fourth quarter of 2024.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Acrivon Therapeutics, Inc. |
|
|
|
|
| Dated: September 16, 2024 |
|
|
|
By: |
|
/s/ Peter Blume-Jensen |
|
|
|
|
Name: |
|
Peter Blume-Jensen, M.D., Ph.D. |
|
|
|
|
Title: |
|
Chief Executive Officer and President |
Exhibit 99.1
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing
ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data
Analysis
- Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5)
observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer
- Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based
on OncoSignature patient selection (p-value = 0.009)
- ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut)
- Endometrial cancer now anticipated to be the first tumor type with potential for ACR-368
accelerated regulatory approval
- IND clearance and initial sites activated ahead of timelines for ACR-2316 with first-in-human dosing anticipated in Q4 2024
- AP3 Interactome generating proprietary, actionable insights, leveraging in-house data and
delivering algorithm-based machine learning-enabled pathway and biomarker analyses
- Acrivon to host a webcast joined by
endometrial cancer key opinion leader Dr. Ramez N. Eskander today, Saturday, September 14 at 9:00 a.m. ET
WATERTOWN, Massachusetts, September 14, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon
Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to
patients whose disease is predicted sensitive to the specific treatment, today presented additional positive clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368
in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug (IND) application for its next clinical candidate, ACR-2316, has
been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024.
“We are very excited to provide several significant, positive updates across our rapidly advancing clinical pipeline since our last R&D event in
April,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. “First, at ESMO earlier today, we presented an updated interim efficacy and safety data cut of our registrational intent
ACR-368 Phase 2 study, which showed a confirmed ORR of 62.5% in endometrial cancer patients. Notably, endometrial cancer is a tumor type that we predicted to be sensitive to single agent ACR-368 with our AP3 indication finding screening approach which we have now confirmed in the clinic. The maturing data is particularly encouraging as the lower bound of the 95% confidence interval is now 30%, above
our targeted goal for this metric. Moreover, while median duration of response has not yet been reached, it is now approximately 6 months with all responding patients on therapy at time of data cut-off. Given
the strength of the data we believe endometrial cancer might provide the first potential approval opportunity for ACR-368. We are actively evaluating potential confirmatory trial designs, including front line,
for a potential future label expansion. We are also excited to disclose that the FDA has cleared the IND for our second clinical program, ACR-2316, well ahead of original timeline projections. Clinical trial
sites have been activated and are now actively screening patients for enrollment into a Phase 1 study. Today’s update further strengthens the validation of our prospective OncoSignature patient selection method and of our differentiated AP3
platform delivering actionable data across discovery and development.”
ACR-368 Updates and Highlights
| |
• |
|
Presented data at ESMO from the ongoing, registrational-intent, multicenter Phase 2 trial of ACR-368 in patients with high grade endometrial cancer. Importantly, all patients enrolled must have progressed on prior anti-PD-1
therapy, unless ineligible. The data were based on 35 safety-evaluable subjects, of which 23 (8 BM+ and 15 BM-) were efficacy-evaluable with at least one on-treatment
scan (data cut off July 25, 2024). |
| |
• |
|
Reported a confirmed ORR (RECIST 1.1) of 62.5% (95% CI, 30.4-86.5)
observed in the cohort of prospectively-selected OncoSignature-positive (BM+) patients who were efficacy-evaluable. Endometrial cancer is a tumor type that was predicted to be sensitive to ACR-368 by AP3-enabled indication screening before any clinical data was generated. |
| |
• |
|
Median duration of response (mDOR) was not yet reached (~6 months at time of data
cut-off); all responding patients still on therapy |
| |
• |
|
Best overall response (BOR) in last prior line predominantly progressive disease (PD) in confirmed ACR-368 responders |
| |
• |
|
Confirmed responses were observed across molecular and histological subtypes |
| |
• |
|
Demonstrated the ability of the AP3-based
ACR-368 OncoSignature assay to prospectively predict patients sensitive to ACR-368 monotherapy based on updated data that showed a clear segregation of responders in the
BM+ versus OncoSignature-negative (BM-) arms (p-value = 0.009) |
| |
• |
|
Observed further evidence of sensitization to ACR-368 by ultra-low dose gemcitabine (ULDG) in a proportion of BM- subjects, with an initial disease control in 8 out of 15 subjects, including 1 confirmed complete response (CR)
|
| |
• |
|
Consistent with past trials and earlier reported data from this trial, the
ACR-368 treatment-related adverse events observed were limited, predominantly transient, reversible, mechanism-based hematological AEs, which typically occurred during the first
1-2 cycles of therapy. There was a notable absence of long-lasting myelosuppression, or the typical more severe non-hematological AEs commonly seen with ADCs and
chemotherapy. |
| |
• |
|
Company conducted a blinded third-party KOL market research study which showed strong interest in the emerging
clinical profile of ACR-368 (product name blinded) as an important potential therapy in the rapidly evolving treatment landscape of endometrial cancer where second line options are now limited due to anti-PD-1 and chemotherapy having been approved in front line therapy |
| |
• |
|
An estimated ~30K new cases of high-grade, locally advanced or metastatic, recurrent (progressed on anti-PD-1 and chemotherapy) endometrial cancer per year |
| |
• |
|
~90% of these patients will progress to second line |
| |
• |
|
The recent approval of pembrolizumab plus chemotherapy as a first-line treatment leaves a significant unmet need
in the second-line, where the bar from reported chemotherapy efficacy in second-line is an ORR of 14.7% and mPFS of 3.8 months (Makker et al; N Engl J Medicine, 2022) |
| |
• |
|
The ESMO poster presentation is available on Acrivon’s website in the “Science and Publications”
section |
ACR-2316 Updates
| |
• |
|
The company today disclosed that the FDA has cleared the IND for its novel, dual WEE1/PKMYT1 inhibitor ACR-2316, ahead of projected timelines |
| |
• |
|
Multiple clinical sites have been activated for the Phase 1 dose optimization study |
| |
• |
|
Initial patient dosing expected in fourth quarter 2024 in selected tumor types |
AP3 Interactome Updates
| |
• |
|
Proprietary, computational analytics platform leveraging machine learning now further advanced for integrated
comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets. |
| |
• |
|
Integration enables quantitative analyses to generate actionable insights for rational drug design, predictive
biomarkers, resistance mechanisms, and indication finding to be implemented in the clinic |
| |
• |
|
AP3 Interactome has been deployed to enable indication finding and patient responder identification for ACR-368 and to generate the novel dual WEE1/PKMYT1 inhibitor ACR-2316 |
Company Webcast and KOL Participation
The company will
host a webcast today, Saturday, September 14 at 9:00 a.m. ET to further discuss these data and pipeline updates. A link to the webcast can be found on the investors page of www.acrivon.com.
In addition to company executives, Ramez N. Eskander, M.D., assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, University of
California, San Diego, CA, a key opinion leader in endometrial cancer will participate in the webcast. Dr. Eskander is the lead author on the influential paper “Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer” (N
Engl J Med (2023) 388(23):2159-2170).
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be
sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific
effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the
identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently
advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The
company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with
platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in
two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368.
The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of
ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for
developing its co-crystallography-driven, internally-discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a potent,
selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors. The company is also progressing internally- developed preclinical programs, including a cell cycle
program with an undisclosed target.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of
operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because
they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are
based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties
that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon
undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
CORPORATE R&D EVENT September 14,
2024 ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE Exhibit 99.2
Forward-looking statements Certain
information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans
and objectives of management for future operations. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,”
“will,” or “would” or the negative of these words or other similar terms or expressions. Our forward-looking statements are based primarily on our current expectations and projections about future events and trends that we
believe may affect our business, financial condition and results of operations. The outcome of the events described in the forward-looking statements is subject to risks and uncertainties, including the factors described in our filings with the U.S.
Securities and Exchange Commission. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this
presentation. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking
statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to update any forward-looking statements or to reflect new information
or the occurrence of unanticipated events, except as required by law.
outline Acrivon Therapeutics and AP3
overview Data update on the prospective ACR-368 registrational intent Phase 2 trial in endometrial cancer Update on ACR-2316, an AP3-derived dual WEE1/PKMYT1 inhibitor cleared for Phase 1 Intro to AP3 Interactome v.2: Real-time actionable analyses
of Acrivon proprietary AP3 data Live Q&A For a comprehensive corporate deck, please visit: https://Acrivon.com
Acrivon Therapeutics – a
next-generation precision medicine company Neurological Cancer Inflammatory Fibrosis Drug P Metabolic Acrivon Predictive Precision Proteomics (AP3) Enables an exact match between the disease-driving, dysregulated pathways with a drug’s
mechanism of action (Acrivon meaning ≈ exact, accurate) Broadly applicable in R&D (biological SAR, resistance, patient responders); leveraged for internal pipeline DNA RNA Protein Dysregulated Protein Dysregulated Pathways +
OncoSignature® Blume-Jensen, P & Hunter, T: Oncogenic kinase signaling Nature (2001) Olsen, JV et al: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell (2006); Andersen, JN et al: Pathway-based
identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors Sci Transl Med (2010)
AP3 developed to overcome Critical
challenges facing biopharma industry Discovering potent compounds suitable for clinical monotherapy Determining which patients will benefit from those drugs Preventing or reducing resistance to maximize response durability AP3 is a proprietary,
machine learning-enabled internal R&D engine that effectively addresses these challenges, driving rapid advancement of our pipeline Challenge Acrivon Predictive Precision Proteomics (AP3) Optimal target/pathway selectivity for rapid generation
of single agent active compounds Identification of drug-sensitive indications and patients for actionable precision medicine Ability to rapidly identify and overcome resistance mechanisms
Acrivon Pipeline Anticipated Next
Milestone Phase 3 Phase 2 Phase 1 Preclinical ACR-368 (CHK1/CHK2) Single-Arm Trials Based on OncoSignature Prediction Option to Initiate Additional Trials in HPV+ SCC (H&N*, Anal, Cervical) and Sarcomas Trial Initiation Q4 2024 Multiple Program
Updates Q3 (ESMO) and Q4 2024 Endometrial Cancer Bladder Cancer OncoSignature-Predicted Monotherapy Sensitive Tumors Future Development Candidates Additional AP3-driven co-crystallography programs ACR-368 Monotherapy LDG Combination Registrational
intent Phase 2 single arm trials based on predicted sensitivity to ACR-368 monotherapy in OncoSignature-positive patients Exploratory Phase 1b/2 single arm trials of ACR-368 in combination with low dose gemcitabine, or LDG, in OncoSignature-negative
patients LDG Combination ACR-368 Monotherapy Fast Track Designation ACR-368 Monotherapy LDG Combination ACR-2316 (WEE1/ PKMYT1) Phase 1 Activated OncoSignature-Predicted Monotherapy Sensitive Tumors Cell cycle program (undisclosed target)
Development Candidate Nomination 2025 Discovery *Investigator-Initiated Trial (IIT) activated at Moffitt Cancer Center Platinum-Resistant Ovarian Cancer ACR-368 Monotherapy Breakthrough Device & Fast Track Designations LDG Combination
Newly disclosed ACR-368 clinical data
ESMO 2024: Interim data from the registrational intent Phase 2 prospective clinical trial in endometrial cancer Data cut as of July 25, 2024 Poster available on Acrivon’s website: https://acrivon.com/science/#publications-posters
AP3-based drug discovery and clinical
development in predicted sensitive subjects and tumor types Predicted Responder AP3 Clinical Biomarkers Predictive OncoSignature tests Indication Finding Sensitive tumor types Resistance Mechanisms Rational drug combinations Drug Discovery SAR
Optimal target selectivity PD Markers ~6,000 per compound Informs in-licensing AP3 profiling of candidates Streamlined Clinical Development Predicted sensitive indications with informed dose optimization
AP3 platform: Drug response prediction in
individual patients “Disease Pathway-Based Method to Generate Biomarker Panels Tailored to Specific Therapeutics for Individualized Treatments”: EP 2 229 589, issued June 10, 2015; US2017/0067877A9, pending.
OncoSignature® is a Registered Trademark: US Reg. No. 5,718,472; Int. Cl. 5, 42. Intl. Reg. 1382289 PROPRIETARY WORKFLOW INTEGRATING PROVEN TECHNOLOGIES STEP 1 STEP 2 STEP 3 BIOMARKER IDENTIFICATION THERAPEUTIC PACKAGE Acrivon drug with
predictive BM assay PATIENT RESPONDERS Optimal indications and combinations AP3 DRUG PROFILING Resistant Sensitive BIOMARKER VALIDATION HIGH RES PROTEOMICS BY MS CELL LINES, PDX, HUMAN TISSUE CLINICAL SIGNATURE ASSAY 3-6 BIOMARKERS PROSPECTIVE
RESPONSE PREDICTION ON PRETREATMENT BIOPSY No benefit Benefit Predicted Non-responder Predicted Responder Patients without biomarkers critical for drug sensitivity efficiently excluded + OncoSignature® CLASS 1 BM CLASS 2 BM CLASS 3 BM
AI-DRIVEN
ACR-368: a clinically active phase 2
CHK1/2 inhibitor ATP-competitive inhibitor of CHK1 (0.9 nM) and CHK2 (8 nM) Exclusively in-licensed from Eli Lilly & Company (WW rights); originally discovered by Array (Pfizer) CoM patent exp. Oct., 2030; Salt-form exp. Apr., 2037 Balanced
inhibition of both CHK1 and CHK2 believed important for RECIST monotherapy activity ACR-368 (MW): 365.4 DRUG TARGET PROFILE AT TIME OF IN-LICENSING Durable monotherapy activity: Platinum-resistant ovarian and squamous cell cancers (Anal and H&N)
Large safety database, favorable safety profile: >1,000 patients treated (~50% mono, ~50% in combination) Ideal for AP3 method: Proven clinical activity, but requires patient responder identification to achieve sufficient ORR G1/S-defective
cancers rely on CHK1-regulated cell cycle checkpoints CHK1 pauses cell cycle to enable DNA repair G2/M Checkpoint S Phase Checkpoint M G1 S Cancer Cell Cycle G2 CHK1/2 CHK1/2 Defective G1/S Checkpoint
Endometrial cancer is an AP3-predicted
ACR-368-Sensitive tumor ACR-368 OncoSignature-based indication finding prior to trial entry ACR-368 OncoSignature imaging demonstrates addiction to CHK1/2 DDR axis Confirmation of predicted sensitivity in genetically non-modified PDX models
Confirmation of ACR-368 OncoSignature prediction in PDX tumor tissues pretreatment in >1,000 cancer patients treated with ACR-368 in Lilly-sponsored trials, endometrial cancer was not tested
High grade advanced stage endometrial
cancer opportunity has opened for ≥ 2nd line (post anti-PD-1) ACR-368 Target Indication: High grade, locally advanced or metastatic, recurrent endometrial cancer Significant unmet need, attractive commercial potential Must have recurred after
prior chemo and PD-1/PD-L1 inhibitor therapy1 Irrespective of molecular (MMR, p53, other) alterations and subtype (serous, endometrioid, clear cell, carcinosarcoma) SOC: ≥2nd line (post-PD-1 + chemo) ~14.7% ORR, mPFS 3.8 months2 ≥3rd
line ~9% ORR, mPFS 2.8 months3 ACR-368 Target Product Profile: ≥25% ORR with CI lower bound >20%; mDoR ≥5.5 months 1Unless ineligible for PD-1/PD-L1 therapy 2Eskander R et al, NEJM, 2023; Mirza MR et al, NEJM, 2023; Makker V et al,
NEJM, 2022 3Ray-Coquard I et al, BJC, 2013
ACR-368-201 Trial and enrollment in
endometrial cancer April 2024 Corporate R&D Event1 ESMO 20242 Endometrial Cancer BM+ BM- Total BM+ BM- Total Safety-Evaluable (enrolled ≥1 dose) 7 11 18 12 23 35 Efficacy-Evaluable (≥1 on-treatment scan) 5 5 10 8 15 23 BM+% (enrolled
BM+/Total) 38.9% 34.3% BM+ BM- https://clinicaltrials.gov/study/NCT05548296 1https://ir.acrivon.com/news-events/events-presentations 2https://acrivon.com/science/#publications-posters Enrollment in Endometrial Cancer ACR-368-201 Trial Ongoing
enrollment in ovarian and bladder cancer cohorts with update planned for future date
Demographics and subject disposition
(N=35) Subject Demographics BM+ N = 12 BM- N = 23 Median Age (range) 66 (60-76) 68 (42-78) Race (%) White 8 (67) 16 (70) Black/African American 3 (25) 3 (13) Asian 0 (0) 3 (13) Other 0 (0) 1 (4) Unknown 1 (8) 0 (0) Current Stage (%) III 3 (25) 12
(52) IV 9 (75) 10 (43) unk 0 (0) 1 (4) Histology (%) Serous 8 (67) 7 (30) Endometrioid 3 (25) 7 (30) Carcinosarcoma 1 (8) 3 (13) Clear Cell Carcinoma 0 (0) 2 (9) Other 0 (0) 4 (17) ECOG Status at Baseline (%) 0 5 (42) 10 (43) 1 7 (58) 13 (57)
Subject Disposition BM+ N = 12 BM- N = 23 Median Prior Lines (range) 2 (1-4) 3 (1-4) Prior PD-1/PD-L1 Therapy (%) Yes 12 (100) 22 (96) No 0 (0) 1 (4)* Discontinued Study Drug (%) 3 (25) 13 (57) Reason for Discontinuing Study Drug (%) PD 2 (17)
10 (43) PI Decision 1 (8) 0 (0) Unacceptable Tox 0 (0) 1 (4) Subject Decision 0 (0) 1 (4) Subject Withdrawal of Consent 0 (0) 1 (4) Survival Status (%) Alive^ 10 (83) 14 (61) Deceased 2 (17) 7 (30) Unknown 0 (0) 2 (9) *Subject deemed ineligible for
anti-PD-1therapy. ^1 BM+ and 4 BM- subjects are still on study for follow-up, but no longer receiving study drug. Data current as of 25July2024 and includes all subjects enrolled with registrational intent BM- includes all subjects treated with
ACR-368 + low dose gemcitabine (LDG) at RP2D (105 mg/m2 and 10 mg/m2, respectively).
significant ACR-368 responder
enrichment in efficacy-evaluable subjects1 (N=23) in registrational intent phase 2 trial Overall Response BM+ Monotherapy BM- LDG Combination Total N = 8 N = 15 N=23 N (%) N (%) N (%) CR 0 (0) 1 (7) 1 (4) cPR 5 (63) 0 (0) 5 (22) uPR 0
(0) 1 (7) 1 (4) SD 1 (13) 6 (40) 7 (30) PD 2 (25) 7 (47) 9 (39) cORR (95% CI) 62.5% (30.4, 86.5) 6.7% (0.84, 31.8) 26% (12.3,46.8) OncoSignature BM+ vs BM- Segregation P = 0.009 Prospective initial validation of the AP3-based ACR-368 OncoSignature
now achieved for endometrial cancer (P = 0.009 vs P = 0.083) Confirmed ORR in BM+ subjects now 62.5% with the lower bound of 95% C.I. 30.4% (vs. 22.9%) Confirmed ACR-368 responders still on therapy; mDoR not yet reached (~6 months at time of
data-cut vs ~2 months) 1Subjects with ≥1 on-treatment scan 2https://ir.acrivon.com/news-events/events-presentations Meaningful positive data maturation since April R&D Event2
Clinical activity in BM+ patients who
have all progressed on prior anti-pd-1 therapy Data current as of 25July2024, includes all BM+ subjects Percent Change from Baseline (sum of diameters) cPR SD PD Still on Treatment Confirmed ORR = 62.5% 95% C.I. (30.4%, 86.5%) Significant disease
control (75%) with most RECIST responses occurring early
Ongoing confirmed responses in BM+
subjects across subtypes Data current as of 25July2024 Months on Treatment 4 – BOR on last prior line 5 – BOR on ACR-368 1 – Subtype 2 – MMR Status mDOR not yet reached (~6 months at time of data cut-off) Durable responses in
patients who all progressed on prior anti-PD-1 and whose BOR in last prior line was mostly PD Most patients are pMMR and p53 mutant, consistent with their prevalence in high grade endometrial cancer ACR-368 OncoSignature prediction is independent of
molecular (incl. MMR) and histological subtype 3 – p53 Status 1 2 3 4 5
Confirmed responses in subjects who
all progressed on prior anti-PD-1 Endometrial subtype # Prior Lines Last Prior Therapy (LPT) BOR on LPT BOR on ACR-368 Serous 3 Pembrolizumab/Lenvatinib PD cPR Serous 2 Pembrolizumab/Lenvatinib PD cPR Endometrioid 4 Cisplatin PD cPR Serous 1
Pembrolizumab SD cPR Carcinosarcoma 2 Pembrolizumab/Lenvatinib PR cPR Serous 4 Liposomal doxorubicin PD SD Serous 3 Pembrolizumab/Lenvatinib UNK PD Serous 3 Pembrolizumab/Lenvatinib NA PD BOR = Best Overall Response, UNK = unknown, NA = not
applicable, NT = not tested Data shown current as of 25Jul2024 and includes all efficacy-evaluable (at least one scan on-treatment) BM+ subjects All confirmed responders progressed on prior PD-1 therapy and majority had BOR = PD on last prior line
of therapy Only 1 RECIST response amongst 6 patients with BOR data from LPT
Deep, rapid responses seen in patients
with large tumor lesions Screening Week 8 Week 16 Superior vaginal cuff Inferior vagina 0 mm 72-yo female with Stage III serous endometrial carcinoma (pMMR) PD on last prior line (pembrolizumab/lenvatinib) Confirmed PR at Week 16 73% overall
decrease in sum of target lesions from baseline
Evidence of LDG sensitization in
proportion of BM- subjects in exploratory phase 1b/2 trial Best Overall Response Initial disease control (1 cCR, 1 uPR, and 6 SD) observed in a proportion of BM- subjects LDG sensitization may potentially increase ORR across BM+ and BM- patients 1 2
3 4 Data current as of 25July2024, includes all BM- subjects enrolled at RP2D for LDG (10 mg/m2). 1– Histology; 2 – MMR; 3 – BOR on most recent prior line; 4 – BOR on ACR-368 + LDG PR SD PD Still on Treatment CR Confirmed
Response Time on Treatment (Weeks) Percent Change from Baseline (sum of diameters) Percent Change from Baseline (sum of diameters) Months on Treatment
Encouraging safety profile Limited,
predominantly transient, reversible, mechanism-based hematological AEs, which typically occurred during the first 1-2 cycles of therapy Notable absence of long-lasting myelosuppression or the typical more severe non-hematological AEs commonly seen
with ADCs and chemotherapy ACR-368 data current as of 25July2024 and includes the safety population of endometrial carcinoma subjects (any subject who has received at least one dose of ACR-368) enrolled (BM+ and BM-) and at the RP2D for LDG (BM-).
Prophylactic G-CSF encouraged in BM+ and mandated in BM- subjects (compatible with q14d dosing regimen). Treatment-Related Adverse Events of Note ACR-368 (BM+) ACR-368 + LDG (BM-) N = 12 N = 23 All (%) Gr 3/4 (%) All (%) Gr 3/4 (%)
Thrombocytopenia 6 (50) 2 (17) 12 (52) 8 (35) Anemia 4 (33) 3 (25) 12 (52) 9 (39) Neutropenia 3 (25) 3 (25) 7 (30) 7 (30) Febrile Neutropenia 0 0 3 (13) 3 (13) Fatigue 3 (25) 0 7 (30) 0 Vomiting 3 (25) 0 2 (9) 0 Diarrhea 2 (17) 0 2 (9) 0 Infusion
Reaction 0 0 1 (4) 0 Hypertension 0 0 1 (4) 1 (4) Dyspnea 0 0 2 (9) 0
blinded KOL Market research
underscores endometrial cancer represents significant opportunity for acr-368 Endometrial cancer (EC) projected to be the third most prevalent cancer and the fourth leading cause of cancer-related death among women by 20401 Incidence = 67,880,
prevalence = 865,000 in the US (2023)*; Incidence increasing by 1-3% per year Mortality = 13,250 in the US (2023); 5-year survival ~ 80%* High grade EC accounts for majority of EC deaths each year Second line (2L) now represents a high unmet need
New cases of high grade, recurrent EC (progressed on anti-PD-1 + chemo) ~30K patients/year 90% of cases believed to progress to 2L therapy Recent front-line approvals of anti-PD-1 plus chemo followed by anti-PD-1 only1,2 for high grade EC
reduces/eliminates pembro + lenvatinib3 as viable 2L option for most patients Reported chemotherapy efficacy in 2L is ORR = 14.7% and mPFS = 3.8 months3 *SEER database 1Eskander et al, NEJM 2023; 2Mirza et al, NEJM 2023; 3Makker et al, NEJM
2022
Blinded Kol market research suggests
acr-368 profile attractive to gynecologic oncologists Themes Implications Representative quotes Significant SOC gap and unmet need exists in 2L opportunity for ACR-368 Huge unmet need still exists in endometrial cancer treatment, especially pMMR
”People that develop recurrence almost invariably do not survive their endometrial cancer.” “That's really where there is the biggest opportunity is – in 2L.” “I would say that you would really want to see
something with a response rates north of 30% to really get people excited about that but really the bar is above 20% and would be interesting.” “I know the FDA is very interested in companion diagnostics. I think that they really want to
see that the work is being done to understand the responders.” Biomarker driven approach highly attractive and justified for high ORR “I believe that in pMMR the contribution of immune therapy is modest.” “If you had a 20% or
25% response rate, that would be pretty good” “If you could predict which patients would respond so that the patients that you chose would be higher, then I think you'd be in like Flynn.” “I think everybody's struggling with
what to do for 2L therapy.” Clinicians eager to embrace new therapeutic options especially in challenging to treat molecular sub-groups “Those patients (pMMR) we know they don't have as robust as response as those patients that are
mismatch repair deficient. Certainly, that's a big unmet need.” Recent changes to standard of care leaves opportunity for significant penetration with new 2L therapies That ACR-368 OncoSignature is independent of genetic background or
histology further favorably differentiates the agent Source: Single blinded, proprietary third-party market research with endometrial KOLs conducted August-September 2024 “Over 60% ORR? I hope such a compound really exists!”
Symptoms (i.e. bleeding, pain)
Evolving Treatment Landscape for the Management of Advanced Stage or Recurrent Endometrial Cancer Diagnosis Surgical Staging Carboplatin + Paclitaxel + Immune Checkpoint Inhibition US FDA Approved in the dMMR and pMMR populations - C/P +
Pembrolizumab (NRG GY018) - C/P + Dostarlimab (RUBY/GOG 3031) NCCN Compendium Listed - C/P + trastuzumab (HER2+ serous and carcinosarcoma) - C/P alone MAINTENANCE Pembrolizumab Dostarlimab ------------ Trastuzumab Progression-Free Survival (9-13
months in the pMMR EC population) Progression Lenvatinib + Pembrolizumab -------------- C/P + IO -------------- US FDA approval of T-Dxd In HER2 3+ Other Lines of Therapy and Clinical Trials Post-Progression Survival (12-18 months) No Prior-IO
Prior-IO Single agent vs combination Chemotherapy -------------- US FDA approval of T-Dxd In HER2 3+ Progression With chemotherapy: ORR 15%; mPFS 3.8 mo Potential alternate strategies: hormonal therapy, single agent IO, T-Dxd in HER 2 2+ (NCCN)
Courtesy Dr. R. Eskander
Development path for ACR-368 in
endometrial cancer Accelerated approval pathway Ongoing single arm registrational intent Phase 2 monotherapy endometrial cancer trial represents the first potential approval opportunity for ACR-368 Confirmatory trial strategy Evaluating options to
potentially move towards new front line setting Randomization anti-PD-1 vs anti-PD-1 + ACR-368 post C/P + anti-PD-1 (sub-group analysis; MMR status in all-comer)* Potential ≥2nd line options: ACR-368 + ULDG in all-comer patients *Based on
current clinical data showing cPRs in patients progressing on prior anti-PD-1 together with a strong rationale for, and preclinical data demonstrating additive/synergistic activity of ACR-368 and anti-PD-1 (Refs: Lyer et al, Cancer Disc 2021;
McGrail et al, Sci Transl Med 2021; Sen et al, Cancer Disc 2019)
ACR-368 potential in high unmet tumor
types beyond endometrial, ovarian, and bladder cancer Enrollment is continuing in our ongoing multicenter phase 2 trials in ovarian and bladder cancer with planned update at a future date ACR-368 has also shown promising clinical activity in HPV+
squamous cell cancers (SCC), and sarcomas* HPV+ SCC are of increasing incidence (~50,000-60,000 new cases per year in the US) and includes ~70-80% of oropharyngeal H&N, ~20% of esophageal, ~90% of cervical, and 95% of anal cancers** SCCHN: Dr. C
Chung, MD, Chair, Moffitt Cancer Center has begun an investigator-initiated trial with ACR-368 + ULDG in both HPV+ and HPV- SCCHN post anti-PD-1. IND cleared and site is activated HPV+ SCC represent tumor types of high unmet need and attractive
option for next Acrivon-sponsored trial(s) with ACR-368 *Hong et al, CCR 2018, Slotkin et al, ASCO Annual Meeting 2022 **CDC 2023; ICO/IARC Information Centre on HPV and Cancer 2023; Gribb et al, Dela J Public Health 2023, NCI 2023
ACR-2316, a potent, novel, dual
WEE1/PKMYT1 inhibitor optimized for superior single agent activity and therapeutic index IND CLEARED AND FIRST CLINICAL SITES ACTIVATED AHEAD OF SCHEDULE AP3-BASED DRUG DISCOVERY
Streamlined AP3-based design of
compounds for superior single agent activity and therapeutic index Peptide clean up Direct DIA analysis Drug treatment Proteolysis P-peptide enrichment Ultra high resolution P-proteomic profiling Week 0 Week 2 Turnaround <2 weeks Quantitative
mapping (>105,000 phospho-sites covering >10,000 proteins) Drug-regulated phospho-sites and biological process enrichment Drug-regulated pathway activity mapping and reconstitution P P AP3 enables pathway-based drug design for optimal drug
properties High resolution and throughput MS-based P-proteomics
ACR-2316: uniquely enabled by AP3 to
overcome limitations of current wee1 and pkmyt1 inhibitors Zhu et al, J. Med. Chem. (2017) Program goals (superior therapeutic index): Superior single agent activity (AP3) Potent activation of CDK1, CDK2, and PLK1 and quenching of resistance through
balanced WEE1/PKMYT1 inhibition to ensure robust pro-apoptotic tumor death High selectivity for minimal AEs (co-crystallography) Structure-guided design to limit adverse events (AEs) to be strictly mechanism-based, transient, short-lived Streamlined
clinical development (ACR-2316 OncoSignature) To identify/prioritize sensitive indications prior to clinical start and for drug target engagement-based dose optimization during Phase 1 AP3 used for pathway-based optimization to achieve superior
single agent activity Co-crystallography for drug design and selectivity ACR-2316: Rationally designed WEE1/PKMYT1 inhibitor Superior anti-tumor efficacy with complete tumor regression across models High selectivity ensures transient, short-lived,
mild AEs Potent WEE1 inhibition, balanced PKMYT1 inhibition, overcomes resistance and enables robust activation of CDK1, CDK2, and PLK1 for mitotic catastrophe
ACR-2316 is highly potent across human
tumor cell lines and patient-derived ex vivo tumor models Patient-derived ex vivo ovarian tumor models Human tumor cell lines (not genetically selected) Breast Lung Ovarian Prostate Renal Medulloblastoma Glioblastoma Pancreatic WEE1i
PKMYT1i
ACR-2316 induces complete tumor
regression across models and dosing regimens 5d on/2 d off Model 1 5d on/2 d off Model 2
ACR-2316 - favorable preclinical
safety profile Mice: ACR-2316 was well-tolerated, resulting in tumor regression in xenograft mouse models at multiple dosing regimens (qw, 2qw, 3d on/4d off, 5d on/2d off, and qd) Transient, reversible, mechanism-based hematological adverse events
Rat and dog MTD, DRF, and GLP tox studies: GLP tox studies (31 days) completed in rat and dog with the planned human dosing regimen achieving exposure required for tumor regression Adverse events were mechanism-based, short-lived, reversible and
limited to dividing myeloid progenitors and gastrointestinal tract We believe the broad therapeutic index observed across all our preclinical studies conducted with the planned dosing regimen is consistent with the target human exposure required for
anti-tumor activity and anticipated reversibility of mechanism-based AEs
ACR-2316 IND cleared and initial
clinical sites activated ACR-2316-101: Phase 1 study of ACR-2316 in subjects with advanced solid tumors Aiming for streamlined clinical development: Multiple sites currently activated and screening, first dosing expected shortly AP3-based indication
finding and OncoSignature development ongoing Dose optimization to be guided by drug target engagement aligned with Project Optimus Dose Expansion RP2D determination in 2 selected tumor types Dose Escalation (N ≤ 42 patients) In selected solid
tumor types
Acr-2316 is a potentially
best-in-class agent rationally designed using Acrivon’s ap3 platform Program Goals Demonstrated Preclinical Results Superior single agent activity High selectivity and potency Streamlined clinical development Favorable safety profile Broad
preclinical therapeutic index and anti-tumor activity across dosing regimens 5-20-fold more potent* in preclinical models than clinical benchmarks High selectivity results in adverse events limited to transient, short-lived, mechanism-based,
reversible Superior* single agent anti-tumor activity through robust CDK1, CDK2, and PLK1 activation and elimination of dominant resistance mechanisms through balanced WEE1 and PKMYT1 inhibition AP3-Enabled SAR AP3-based identification of PD
biomarkers and prioritization of promising indications 1 2 3 4 *Head-to-head preclinical studies against benchmarks with clinical data
Data completeness Peptide IDs CV
Pearson Correlation PCA Hierarchical Clustering DEPs Volcano Plots ANOVA Hierarchical clustering Consensus Sequence Motif Kinase Inference Pathway Enrichment Network Mapping Biomarkers Filtering Batch effects Normalization Imputation ~150,000
phosphosites ~50,000 phosphosites Ap3 interactome v.2: Proprietary Interactive Data analysis infrastructure Actionable data across all AP3 experiments accessible for all Acrivon scientists Fully scripted, algorithm-based machine learning-enabled
pathway and biomarker analyses
Acr-2316 induces potent activation of
pro-apoptotic mitotic kinases in sensitive tumor cells Robust activation of CDK1with ACR-2316 exemplified by enrichment of 206 upregulated substrates of CDK1 ACR-2316 @60min and 200nM in ACHN
Robust potent inhibition of CDK1
consensus substrate Y15 by ACR-2316 AP3 interactome enables real time quantitative computational analyses of proprietary AP3 drug profiling data across different conditions and experiments Comparison @60min and 200nM in ACHN Time-dependent
comparison @ 200nM in ACHN Dose-dependent comparison @ 60min in ACHN ACR-2316 ACR-2316 3 -3 log2FC 3 -3 log2FC 3 -3 log2FC
Robust potent inhibition of CDK1
consensus substrate Y15 by ACR-2316 vs comparators 60min and 200nM in ACHN 3 -3 log2FC
Robust potent inhibition of CDK1
consensus substrate Y15 by ACR-2316 vs comparators Dose-dependent comparison @ 60min in ACHN 3 -3 log2FC
Robust potent inhibition of CDK1
consensus substrate Y15 by ACR-2316 vs comparators Time-dependent comparison @ 200 nM in ACHN 3 -3 log2FC
AP3-based compound design in intact
cells: optimal activation and inhibition of critical pathways CDK1, CDK2, and PLK1 top activated kinases critical for potent pro-apoptotic tumor cell death (mitotic catastrophe) top inhibited kinases involved in resistance to WEE1
inhibitors
FINANCIAL HIGHLIGHTS Cash and
marketable securities $220.4M Projected runway into H2’26 Fully Diluted Shares Outstanding 43.9M Balance sheet 30-June-2024 Current operating plan, assuming no additional financing Including shares, pre-funded warrants and equity grants
outstanding 30-June-2024
Key take aways Significant clinical
advancements and continued prospective validation of our AP3 platform since last R&D update in April Interim registrational intent Phase 2 clinical data for ACR-368 endometrial cancer cohort*, with confirmed ORR (63%) and lower bound of
confidence interval (~30%), solidifying endometrial cancer as likely first indication for potential approval Statistically significant segregation of responders in BM+ vs BM- subgroups based on prospective OncoSignature patient selection (p-value =
0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) IND clearance of ACR-2316, a potential best-in-class, dual WEE1/PKMYT1 inhibitor rationally designed using
AP3; clinical sites activated and screening patients for enrollment in a Ph1b study AP3 Interactome generating proprietary, actionable insights, leveraging in-house data and delivering fully scripted, algorithm-based machine learning-enabled pathway
and biomarker analyses 1 2 3 4 5 Cash and marketable securities ~$220M with runway projected into second half of 2026 6 * Data cut as of July 25, 2024 Actively evaluating potential confirmatory trial designs for a potential future label expansion
7
Infectious, CNS, and other diseases
Oncology Fibrotic and inflammatory Autoimmune Cancers with DDR stress Therapeutic areas Therapeutic modalities Small molecule Bifunctional molecule Antibody ADC Oligo/RNA The AP3 Approach is modality and disease agnostic Current focus
Q&A session
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Acrivon Therapeutics (NASDAQ:ACRV)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Acrivon Therapeutics (NASDAQ:ACRV)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
